$AXGN
Axogen, Inc. Stock $axgn

$axgn Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000080592822000026 Filed on February 25, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$31.54M	$127.4M	$32.50M
YoY Change	-2.95%	13.41%	15.39%
Cost Of Revenue	$6.106M	$22.93M	$6.120M
YoY Change	-0.23%	6.26%	12.71%
Gross Profit	$25.43M	$104.4M	$27.03M
YoY Change	-5.92%	15.11%	16.11%
Gross Profit Margin	80.64%	81.99%	83.19%
Selling, General & Admin	$24.48M	$105.7M	$26.82M
YoY Change	-8.72%	10.01%	6.26%
% of Gross Profit	96.27%	101.19%	99.22%
Research & Development	$6.302M	$24.18M	$4.930M
YoY Change	27.83%	35.48%	0.41%
% of Gross Profit	24.78%	23.15%	18.24%
Depreciation & Amortization	$716.0K	$2.721M	$560.0K
YoY Change	27.86%	80.56%	69.7%
% of Gross Profit	2.82%	2.61%	2.07%
Operating Expenses	$30.78M	$129.8M	$31.75M
YoY Change	-3.04%	14.0%	5.31%
Operating Profit	-$5.353M	-$25.42M	-$4.718M
YoY Change	13.46%	9.64%	-31.31%
Interest Expense	$208.0K	$1.356M	-$610.0K
YoY Change	-134.1%	28.65%	-241.86%
% of Operating Profit
Other Income/Expense, Net	-$141.0K	-$1.569M	-$20.00K
YoY Change	605.0%	159.77%	-60.0%
Pretax Income	-$5.286M	-$26.99M	-$6.010M
YoY Change	-12.05%	13.38%	-14.63%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$5.286M	-$26.99M	-$6.010M
YoY Change	-12.05%	13.45%	-14.61%
Net Earnings / Revenue	-16.76%	-21.19%	-18.5%
Basic Earnings Per Share		-$0.65
Diluted Earnings Per Share	-$127.1K	-$0.65	-$149.3K
COMMON SHARES
Basic Shares Outstanding	41.56M shares	41.22M shares	40.13M
Diluted Shares Outstanding		41.22M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$84.09M	$84.09M	$104.0M
YoY Change	-19.15%	-19.15%	7.77%
Cash & Equivalents	$32.76M	$32.76M	$48.77M
Short-Term Investments	$51.33M	$51.33M	$55.20M
Other Short-Term Assets	$8.086M	$8.086M	$11.10M
YoY Change	-27.15%	-27.15%	44.16%
Inventory	$16.69M	$16.69M	$12.53M
Prepaid Expenses
Receivables	$18.16M	$18.16M	$17.62M
Other Receivables	$26.00K	$26.00K	$0.00
Total Short-Term Assets	$127.0M	$127.0M	$145.3M
YoY Change	-12.53%	-12.56%	7.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$62.88M	$78.12M	$38.40M
YoY Change	63.76%	44.39%	157.93%
Goodwill
YoY Change
Intangibles	$2.859M		$2.054M
YoY Change	39.19%		35.58%
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change
Total Long-Term Assets	$80.98M	$80.98M	$56.13M
YoY Change	44.26%	44.34%	186.06%
TOTAL ASSETS
Total Short-Term Assets	$127.0M	$127.0M	$145.3M
Total Long-Term Assets	$80.98M	$80.98M	$56.13M
Total Assets	$208.0M	$208.0M	$201.4M
YoY Change	3.3%	3.29%	30.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.923M	$5.923M	$4.597M
YoY Change	28.84%	28.76%	-44.36%
Accrued Expenses	$18.36M	$18.36M	$18.20M
YoY Change	0.88%	0.88%	44.44%
Deferred Revenue	$14.00K		$14.00K
YoY Change	0.0%		0.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.000K	$9.000K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$24.29M	$24.29M	$22.83M
YoY Change	6.4%	6.55%	9.34%
LONG-TERM LIABILITIES
Long-Term Debt	$44.82M	$44.83M	$32.03M
YoY Change	39.95%	40.08%
Other Long-Term Liabilities	$0.00	$26.36M	$3.000K
YoY Change	-100.0%	12.63%	-80.0%
Total Long-Term Liabilities	$44.82M	$71.18M	$32.03M
YoY Change	39.93%	28.49%	213433.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.29M	$24.29M	$22.83M
Total Long-Term Liabilities	$44.82M	$71.18M	$32.03M
Total Liabilities	$95.47M	$95.47M	$78.23M
YoY Change	22.04%	22.09%	247.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$230.6M		-$203.6M
YoY Change	13.25%		13.22%
Common Stock	$343.2M		$326.8M
YoY Change	5.01%		4.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$112.6M	$112.6M	$123.1M
YoY Change
Total Liabilities & Shareholders Equity	$208.0M	$208.0M	$201.4M
YoY Change	3.3%	3.29%	30.22%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$5.286M	-$26.99M	-$6.010M
YoY Change	-12.05%	13.45%	-14.61%
Depreciation, Depletion And Amortization	$716.0K	$2.721M	$560.0K
YoY Change	27.86%	80.56%	69.7%
Cash From Operating Activities	-$1.514M	-$13.41M	$2.830M
YoY Change	-153.5%	39.26%	-184.98%
INVESTING ACTIVITIES
Capital Expenditures	-$7.225M	$27.81M	-$3.300M
YoY Change	118.94%	26.96%	184.48%
Acquisitions
YoY Change
Other Investing Activities	-$6.360M	$4.751M	-$16.06M
YoY Change	-60.4%	-15.61%	-208.96%
Cash From Investing Activities	-$13.59M	-$23.65M	-$19.35M
YoY Change	-29.79%	39.42%	-242.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.043M	$20.45M	4.510M
YoY Change	-76.87%	-49.47%	395.6%
NET CHANGE
Cash From Operating Activities	-1.514M	-$13.41M	2.830M
Cash From Investing Activities	-13.59M	-$23.65M	-19.35M
Cash From Financing Activities	1.043M	$20.45M	4.510M
Net Change In Cash	-14.06M	-$16.60M	-12.01M
YoY Change	17.04%	-219.57%	-207.62%
FREE CASH FLOW
Cash From Operating Activities	-$1.514M	-$13.41M	$2.830M
Capital Expenditures	-$7.225M	$27.81M	-$3.300M
Free Cash Flow	$5.711M	-$41.22M	$6.130M
YoY Change	-6.84%	30.72%	-382.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000805928
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20191231/20211231#LeaseLiabilityCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20191231/20211231#LeaseLiabilityCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20191231/20211231#LeaseLiabilitiesNoncurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20191231/20211231#LeaseLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20191231/20211231#LeaseLiabilityCurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20191231/20211231#LeaseLiabilityCurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20191231/20211231#LeaseLiabilitiesNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20191231/20211231#LeaseLiabilitiesNoncurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36046
CY2021	dei	Entity Registrant Name EntityRegistrantName	AXOGEN, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MN
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	13631 Progress Blvd., Suite 400
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Alachua
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	41-1301878
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32615
CY2021	dei	City Area Code CityAreaCode	386
CY2021	dei	Local Phone Number LocalPhoneNumber	462-6800
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2021	dei	Trading Symbol TradingSymbol	AXGN
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	641907222	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	55199000	USD
CY2021	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41795240	shares
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	Miami, Florida
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32756000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48767000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	6251000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	6842000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	51330000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	276000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	416000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18158000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17618000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	16693000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	12529000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1861000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4296000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	127049000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	145251000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62881000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38398000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15193000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15614000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	64000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2859000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2054000	USD
CY2021Q4	us-gaap	Assets Assets	208024000	USD
CY2020Q4	us-gaap	Assets Assets	201381000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	22459000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21968000	USD
CY2021Q4	axgn	Lease Liability Current LeaseLiabilityCurrent	1834000	USD
CY2020Q4	axgn	Lease Liability Current LeaseLiabilityCurrent	863000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24293000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22831000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	44821000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	32027000	USD
CY2021Q4	axgn	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	20798000	USD
CY2020Q4	axgn	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	20874000	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5562000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2497000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	95474000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	78232000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41736950	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41736950	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40618766	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40618766	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	417000	USD
CY2019	us-gaap	Revenues Revenues	106712000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22931000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	406000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	342765000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	326390000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-230632000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-203647000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	112550000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	123149000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	208024000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	201381000	USD
CY2021	us-gaap	Revenues Revenues	127358000	USD
CY2020	us-gaap	Revenues Revenues	112300000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21581000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17349000	USD
CY2021	us-gaap	Gross Profit GrossProfit	104427000	USD
CY2020	us-gaap	Gross Profit GrossProfit	90719000	USD
CY2019	us-gaap	Gross Profit GrossProfit	89363000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	73328000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	69659000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	71950000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24177000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17846000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17514000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32338000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26396000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31305000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	129843000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	113901000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	120769000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-25416000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-23182000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-31406000	USD
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	93000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	605000	USD
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	2364000	USD
CY2021	us-gaap	Interest Expense InterestExpense	1356000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1054000	USD
CY2019	us-gaap	Interest Expense InterestExpense	40000	USD
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-28000	USD
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-117000	USD
CY2019	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	278000	USD
CY2020	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	38000	USD
CY2019	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	53000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1569000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-604000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2271000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26985000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23786000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29135000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41215000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41215000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39967000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39967000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39235000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39235000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	146982000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10304000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4002000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29135000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	132153000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8470000	USD
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2020	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	670000	USD
CY2020	axgn	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	3300000	USD
CY2020	axgn	Stock Issued During Period Settlement Of Warrants And Rights Value StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue	3682000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23786000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	123149000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10919000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10919000	USD
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2021	axgn	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	5467000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26985000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	112550000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26985000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23786000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29135000	USD
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	2721000	USD
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1507000	USD
CY2019	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	933000	USD
CY2021	axgn	Right Of Use Asset Amortization RightOfUseAssetAmortization	1818000	USD
CY2020	axgn	Right Of Use Asset Amortization RightOfUseAssetAmortization	1800000	USD
CY2019	axgn	Right Of Use Asset Amortization RightOfUseAssetAmortization	1821000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	202000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	153000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	123000	USD
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2019	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	104000	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	831000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	232000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-41000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-105000	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	514000	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	3314000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	2242000	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	1887000	USD
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-68000	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	47000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	972000	USD
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-28000	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-117000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10919000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	8470000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	10304000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	499000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	635000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2136000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7478000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	910000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3767000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2435000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2524000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	661000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-270000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4958000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2920000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	463000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1086000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	1773000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	34000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1420000	USD
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	3000	USD
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-12000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-30000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13405000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9626000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19872000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27811000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21905000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4664000	USD
CY2021	axgn	Proceeds From Grantors Investing Activities ProceedsFromGrantorsInvestingActivities	950000	USD
CY2020	axgn	Proceeds From Grantors Investing Activities ProceedsFromGrantorsInvestingActivities	0	USD
CY2019	axgn	Proceeds From Grantors Investing Activities ProceedsFromGrantorsInvestingActivities	0	USD
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	68699000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	77806000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	121074000	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	72500000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	83440000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	153571000	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	589000	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	692000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	562000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23649000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16963000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27271000	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	35000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	7820000	USD
CY2019	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	7820000	USD
CY2019	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3500000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	642000	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	15000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	14000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	-29000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	5467000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3300000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4002000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	670000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20452000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40474000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4031000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16602000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13885000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11430000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55609000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41724000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30294000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39007000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55609000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41724000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	495000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	822000	USD
CY2020	axgn	Noncash Right Of Use Assets And Operating Lease Liability NoncashRightOfUseAssetsAndOperatingLeaseLiability	14259000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1077000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3212000	USD
CY2019	axgn	Noncash Right Of Use Assets And Operating Lease Liability NoncashRightOfUseAssetsAndOperatingLeaseLiability	26000	USD
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	5250000	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2021	axgn	Embedded Derivative Associated With The Long Term Debt EmbeddedDerivativeAssociatedWithTheLongTermDebt	3037000	USD
CY2020	axgn	Embedded Derivative Associated With The Long Term Debt EmbeddedDerivativeAssociatedWithTheLongTermDebt	2563000	USD
CY2019	axgn	Embedded Derivative Associated With The Long Term Debt EmbeddedDerivativeAssociatedWithTheLongTermDebt	0	USD
CY2021	axgn	Noncash Right Of Use Assets And Operating Lease Liability NoncashRightOfUseAssetsAndOperatingLeaseLiability	1375000	USD
CY2021	axgn	Noncash Or Part Noncash Conversion Option NoncashOrPartNoncashConversionOption	0	USD
CY2020	axgn	Noncash Or Part Noncash Conversion Option NoncashOrPartNoncashConversionOption	182000	USD
CY2019	axgn	Noncash Or Part Noncash Conversion Option NoncashOrPartNoncashConversionOption	0	USD
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	418000	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2021	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of PresentationThe accompanying consolidated financial statements include the accounts of Axogen, Inc. (the “Company” or “Axogen”) and its wholly owned subsidiaries, Axogen Corporation (“AC”), Axogen Processing Corporation (“APC”) and Axogen Europe GmbH, as of December 31, 2021 and 2020 and for the three years ended December 31, 2021. The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). All intercompany accounts and transactions have been eliminated in consolidation.
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Organization and Business<div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axogen is the leading company focused specifically on the science, development, and commercialization of the technologies for peripheral nerve regeneration and repair. Axogen is passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries. Axogen provides innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axogen’s platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Connector, a porcine (pig) submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; Avive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue conduit and Axotouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Two-Point Discriminator, used to measure the innervation density of any surface area of skin. Axogen's portfolio of products is available in the U.S., Canada, Germany, United Kingdom ("UK"), Spain, South Korea, and several other countries.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axogen suspended the market availability of Avive Soft Tissue Membrane ("Avive") effective June 1, 2021, and management continues discussion with the U.S. Food and Drug Administration (the "FDA") to determine the appropriate regulatory classification and requirements for Avive. The suspension was not based on any safety or product issues or concerns with Avive. Axogen seeks to return Avive to the market, although the Company is unable to estimate the timeframe or provide any assurance that a return to the market will be achievable. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avance Nerve Graft and Avive Soft Tissue Membrane are processed in the U.S. by Axogen pursuant to a License and Services Agreement, as amended, (the "CTS Agreement') with Community Blood Center (doing business as Community Tissue Services) ("CTS") at the CTS processing facility in Dayton, Ohio. The Axoguard product line is manufactured by Cook Biotech Incorporated ("Cook Biotech"), in West Lafayette, Indiana. The Axotouch Two-Point Discriminator is contract manufactured by Viron Technologies, LLC (doing business as Cybernetics Research Laboratories) (“CRL”) in Tucson, Arizona. CRL supplies the Axotouch Two-Point Discriminator unpackaged, and they are packaged at Axogen’s distribution facility in Burleson, Texas.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the outbreak of the 2019 novel coronavirus and any and all variants thereof ("COVID-19") a pandemic. The global impact of COVID-19 has had a negative effect on the global economy, disrupting the financial markets and significantly impacting the medical industry. The Company implemented certain cost mitigation initiatives in 2020 such as a reduction in pay levels, temporary suspension of tissue processing and deferral of certain projects, among other efforts. As economic activity began to normalize, the Company lifted these cost mitigation initiatives.</span></div>Although COVID-19 had a significant impact on the Company's revenue growth in 2020, the Company was able to increase revenue in 2021 as compared to 2020. The rapid development and fluidity of the situation surrounding COVID-19 prevent any prediction as to the ultimate impact COVID-19 will have on the Company's business as new variants continue to spread, causing global supply chain disruptions, labor shortages, and inflationary conditions.
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	32238000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	6251000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	6842000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32756000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48767000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	6251000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	6842000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39007000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55609000	USD
CY2019Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	16944000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	14000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	15000	USD
CY2020Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	17618000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	14000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3000	USD
CY2020	axgn	Increase Decrease In Contract Receivable IncreaseDecreaseInContractReceivable	674000	USD
CY2020	axgn	Increase Decrease In Contract With Customer Liability Current IncreaseDecreaseInContractWithCustomerLiabilityCurrent	0	USD
CY2020	axgn	Increase Decrease In Contract With Customer Liability Noncurrent IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent	-12000	USD
CY2020Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	17618000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	14000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3000	USD
CY2021Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	18158000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	14000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2021	axgn	Increase Decrease In Contract Receivable IncreaseDecreaseInContractReceivable	540000	USD
CY2021	axgn	Increase Decrease In Contract With Customer Liability Current IncreaseDecreaseInContractWithCustomerLiabilityCurrent	0	USD
CY2021	axgn	Increase Decrease In Contract With Customer Liability Noncurrent IncreaseDecreaseInContractWithCustomerLiabilityNoncurrent	-3000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	276000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	416000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24177000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17846000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17514000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Management believes the critical accounting estimates relating to inventory, derivative instruments, and stock-based compensation affect the Company's more significant judgments and estimates used in the preparation of the Company’s consolidated financial statements. Actual results could differ materially from those estimates.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div>
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11011000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8876000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	813000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	751000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4869000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2902000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	16693000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	12529000	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	3314000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	2242000	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	1887000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	0	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2596000	USD
CY2021Q4	axgn	Stock Option Receivable Current StockOptionReceivableCurrent	3000	USD
CY2020Q4	axgn	Stock Option Receivable Current StockOptionReceivableCurrent	2000	USD
CY2021Q4	us-gaap	Insurance Receivable For Malpractice Current InsuranceReceivableForMalpracticeCurrent	23000	USD
CY2020Q4	us-gaap	Insurance Receivable For Malpractice Current InsuranceReceivableForMalpracticeCurrent	23000	USD
CY2021Q4	axgn	Prepaid Events Current PrepaidEventsCurrent	54000	USD
CY2020Q4	axgn	Prepaid Events Current PrepaidEventsCurrent	203000	USD
CY2021Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	620000	USD
CY2020Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	587000	USD
CY2021Q4	axgn	Prepaid Software License Current PrepaidSoftwareLicenseCurrent	215000	USD
CY2020Q4	axgn	Prepaid Software License Current PrepaidSoftwareLicenseCurrent	220000	USD
CY2021Q4	axgn	Prepaid Professional Fees Current PrepaidProfessionalFeesCurrent	207000	USD
CY2020Q4	axgn	Prepaid Professional Fees Current PrepaidProfessionalFeesCurrent	251000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	739000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	414000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1861000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4296000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2596000	USD
CY2020	us-gaap	Depreciation Depreciation	1507000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	22459000	USD
CY2019	us-gaap	Depreciation Depreciation	933000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	70427000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	43223000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7546000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4825000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62881000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38398000	USD
CY2021	us-gaap	Depreciation Depreciation	2721000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	123000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3570000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1086000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2484000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2589000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	884000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1705000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3945000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1086000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2859000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2938000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	884000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2054000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	202000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	153000	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	104000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5923000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	6842000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4597000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6863000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3778000	USD
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	9673000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	13593000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21968000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	5179000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2973000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	44821000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	32027000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	6251000	USD
CY2021	axgn	Share Base Payment Arrangement Number Of Plans ShareBasePaymentArrangementNumberOfPlans	2	plan
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10919000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8470000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10304000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	19502000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3420181	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.69
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M12D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26074000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	663098	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.29
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	107541	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	19.71
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	459254	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.36
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3516484	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.79
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y11M4D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25718000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	656398	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	194301	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.02
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	783843	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.89
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3194738	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.65
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2236000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1865381	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.08
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y11M12D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1932000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	5467000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3300000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3091000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4002000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14167000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5595000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	9553000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	47021000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42317000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	653000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	397000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment		USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2021Q4	axgn	Deferred Tax Assets Interest Limitation DeferredTaxAssetsInterestLimitation	453000	USD
CY2020Q4	axgn	Deferred Tax Assets Interest Limitation DeferredTaxAssetsInterestLimitation	115000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	70000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	106000	USD
CY2021Q4	axgn	Deferred Tax Assets Right Of Use Liability DeferredTaxAssetsRightOfUseLiability	5736000	USD
CY2020Q4	axgn	Deferred Tax Assets Right Of Use Liability DeferredTaxAssetsRightOfUseLiability	5551000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3985000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3218000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57924000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	51704000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	692000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1145000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	116000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	34000	USD
CY2021Q4	axgn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	3861000	USD
CY2020Q4	axgn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	4004000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	4000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	4000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4673000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5187000	USD
CY2021Q4	axgn	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	53251000	USD
CY2020Q4	axgn	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	46517000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53251000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46517000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6734000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6585000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20794000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.073
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.014
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.006
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.043
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.247
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.277
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.208
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	47021000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	116000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	22000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	22000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	22000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4326000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2777000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1910000	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	41000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	744000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	18000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	17000	USD
CY2021	us-gaap	Lease Cost LeaseCost	5104000	USD
CY2020	us-gaap	Lease Cost LeaseCost	2936000	USD
CY2019	us-gaap	Lease Cost LeaseCost	1994000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15193000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15614000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1825000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	846000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	64000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	9000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20864000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	17000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	13000	USD
CY2021	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	1537000	USD
CY2020	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	1913000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	16000	USD
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0723
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0728
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1032
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0944
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4068000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	10000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3247000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	3000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3013000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3097000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	23935000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	40451000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	13000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	17832000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	0	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	22619000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	13000	USD
CY2019Q1	axgn	Threshold Period For Not Filing Response To Complaint ThresholdPeriodForNotFilingResponseToComplaint	P30D

Files In Submission

Name	View Source	Status
0000805928-22-000026-index-headers.html	Edgar Link	pending
0000805928-22-000026-index.html	Edgar Link	pending
0000805928-22-000026.txt	Edgar Link	pending
0000805928-22-000026-xbrl.zip	Edgar Link	pending
a2021consent.htm	Edgar Link	pending
axgn-20211231.htm	Edgar Link	pending
axgn-20211231.xsd	Edgar Link	pending
axgn-20211231_cal.xml	Edgar Link	unprocessable
axgn-20211231_def.xml	Edgar Link	unprocessable
axgn-20211231_g1.jpg	Edgar Link	pending
axgn-20211231_g2.jpg	Edgar Link	pending
axgn-20211231_htm.xml	Edgar Link	completed
axgn-20211231_lab.xml	Edgar Link	unprocessable
axgn-20211231_pre.xml	Edgar Link	unprocessable
axgnfy21q4ex31111.htm	Edgar Link	pending
axgnfy21q4ex31211.htm	Edgar Link	pending
axgnfy21q4ex3211.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
subsidiariesofaxogen123121.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AXGN
Axogen, Inc. Stock $axgn

2021 Q4 Form 10-K Financial Statement

#000080592822000026 Filed on February 25, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXGN Axogen, Inc. Stock $axgn

2021 Q4 Form 10-K Financial Statement

#000080592822000026 Filed on February 25, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXGN
Axogen, Inc. Stock $axgn